Halozyme Therapeutics, Inc. (HALO) Fundamental Analysis: Bull vs. Bear Case

HALO

Halozyme Therapeutics, Inc.

Fundamental data last updated:September 8, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

VALUATION

P/E

22.54 Market Cap ($M USD)

$7.89B

Forward P/E

7.48 PEG

0.04 PRICE TO SALES

5.23 PRICE TO BOOK

35.79 EV / EBITDA

10.13 5-Year Average P/E

Free Cash Flow Yield

8.46%

DCF Value

$166.51

Graham Number

$11.11

Price to FCF

11.82 EV to FCF

14.57 Earnings Yield

4.44%

FCF Yield

8.46%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.95

Next Year EPS Growth Estimate

$8.90

Next Year Revenue Growth Estimate

$1.78B

Return on Equity (ROE)

126.27%

FREE CASH FLOW

Operating Margin

56.96%

Debt-to-Equity

43.89 Piotroski F-Score

6 Altman Z-Score

4.02 Return on Invested Capital (ROIC)

37.21%

Current Ratio

2.76 Quick Ratio

2.33 Net Debt to EBITDA

1.91 Interest Coverage

44.97 Gross Profit margin

76.93%

FCF PER SHARE

$5.65

REVENUE PER SHARE

$12.77

Gainseekers Quantitative Analysis

Summary

Halozyme Therapeutics appears significantly undervalued when juxtaposed against its DCF value, suggesting a potential market mispricing. The Forward P/E of 7.25 indicates a bargain for future earnings, especially with an impressive Earnings Yield of 4.20%. The Altman Z-score of 3.82 underscores financial stability, hinting at low bankruptcy risk. Despite a Price/Book ratio that seems astronomical, the company’s robust Return on Equity of 92.67% suggests exceptional management efficiency and profitability. Overall, the financial health and growth prospects paint a compelling picture for value investors.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Halozyme is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation and research aligns seamlessly with tech integration. This adaptability could enhance their competitive edge in a rapidly evolving market landscape.

The Bull Case

For the discerning GARP investor, Halozyme offers a tantalizing proposition. The ROIC of 34.76% reflects superior capital allocation, while a Piotroski F-Score of 7 signals strong financial health. With a Free Cash Flow Yield of 8.49%, the company demonstrates robust cash generation capabilities. Its impressive operating margin of 58.45% indicates significant pricing power, suggesting that Halozyme can effectively convert sales into profits, a hallmark of a resilient business model.

The Bear Case

Despite its strengths, Halozyme's Price/Book ratio of 154.57 raises eyebrows, suggesting potential overvaluation relative to its book value. The Price/Sales ratio of 5.44 also implies a premium valuation, which could deter cautious investors. Technically, the stock's proximity to its 52-week high, with a mere 28.23% distance, hints at possible overextension. While debt levels are commendably low, these valuation concerns could overshadow its operational efficiencies.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$75.00

Institutional Ownership %

1-Year Beta

0.88 Insider Buying % (6 Mo)

Distance to 52-Week High

23.56%

Distance to 52-Week Low

23.26%

EARNINGS SURPRISE %

3.90%

50-DAY SMA

$66.06

200-DAY SMA

$69.22

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.